Madhav Prasad Yadav

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 201 citations

177Lu-dotatate Prrt, First Clinical Experience, Medicine +9

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Mike Sathekge, Ismaheel O. Lawal, Chandrasekhar Bal et al. · The Lancet Oncology · 2024 · 157 citations

Retrospective Study, Urology, Radiation Medicine +7

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 146 citations

Life Assessment, Urology, Oncology +7

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 144 citations

Positron Emission Tomography, Neuro-oncology, Oncologic Imaging +10

Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo et al. · Theranostics · 2020 · 142 citations · Full text